Stock Events

Stock Events

Immunicum AB 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 11Expected
Q2 2026
Next
-0.04
-0.04
-0.03
-0.03
Expected EPS
-0.042601919999999995
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-10.36MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1YG.MU. It's not an investment recommendation.
Apple
2
AAPL
Tesla
2
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, Inc. has a strong portfolio in oncology and cell therapy, competing in the broader cancer treatment market alongside Immunicum.
Novartis
NVS
Mkt Cap303.67B
Novartis AG is a large pharmaceutical company with a significant investment in cancer immunotherapy, making it a competitor in the oncology space.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. is a leader in immunotherapy with its blockbuster drug Keytruda, competing in the oncology market.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. has a diverse portfolio including oncology and inflammatory disease treatments, competing in the biotechnological space for cancer therapies.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. has a broad range of cancer treatments and invests heavily in oncology research, making it a competitor in the cancer therapy market.

About

Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
Show More
CEO
Erik Manting
Employees
19
Country
Sweden
ISIN
SE0005003654
WKN
000A40CZ4

Listings

STU
DE
1YG0.STU
MU
DE
1YG.MU
F
DE
1YG0.F
MU
DE
1YG0.MU

0 Comments

Share your thoughts

FAQs

What is Immunicum AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Immunicum AB stocks are traded under the ticker 1YG.MU.
When is the next Immunicum AB earnings date?▼
Immunicum AB is going to release the next earnings report on November 11, 2026.
What were Immunicum AB earnings last quarter?▼
1YG.MU earnings for the last quarter are -0.03 EUR per share, whereas the estimation was -0.04 EUR resulting in a +24.44% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Immunicum AB revenue for the last year?▼
Immunicum AB revenue for the last year amounts to 0 EUR.
What is Immunicum AB net income for the last year?▼
1YG.MU net income for the last year is -10.36M EUR.
How many employees does Immunicum AB have?▼
As of November 4, 2026, the company has 19 employees.
In which sector is Immunicum AB located?▼
Immunicum AB operates in the Health & Wellness sector.
When did Immunicum AB complete a stock split?▼
The last stock split for Immunicum AB was on June 3, 2024 with a ratio of 1:20.
Where is Immunicum AB headquartered?▼
Immunicum AB is headquartered in Stockholm, Sweden.